Fennec Pharmaceuticals Files 8-K Amendment
Ticker: FENC · Form: 8-K/A · Filed: Mar 6, 2024 · CIK: 1211583
| Field | Detail |
|---|---|
| Company | Fennec Pharmaceuticals Inc. (FENC) |
| Form Type | 8-K/A |
| Filed Date | Mar 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-condition, filing
TL;DR
Fennec Pharma filed an amendment to its 8-K. Check for updates on financials.
AI Summary
Fennec Pharmaceuticals Inc. filed an amendment (8-K/A) on March 6, 2024, to its report originally dated February 29, 2024. This amendment pertains to the company's results of operations and financial condition, as well as financial statements and exhibits. The filing does not appear to contain new financial figures or operational updates beyond the initial report.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to the initial disclosure regarding Fennec Pharmaceuticals' financial condition and operations.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, likely for clarification or correction, rather than a new material event.
Key Players & Entities
- Fennec Pharmaceuticals Inc. (company) — Registrant
- February 29, 2024 (date) — Date of earliest event reported
- March 6, 2024 (date) — Filing date of the amendment
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previously filed 8-K report, specifically addressing the 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' items.
What was the original report date that this amendment refers to?
The original report date that this amendment refers to is February 29, 2024.
When was this amendment filed with the SEC?
This amendment was filed with the SEC on March 6, 2024.
What are the main items covered by this filing?
The main items covered by this filing are Results of Operations and Financial Condition, and Financial Statements and Exhibits.
Does this amendment introduce new financial information or operational updates?
The filing is an amendment to a previous report and does not appear to introduce significant new financial figures or operational updates beyond what was in the original report, suggesting it's for clarification or correction.
Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-03-06 16:07:35
Filing Documents
- tm248156d1_8ka.htm (8-K/A) — 25KB
- tm248156d1_ex99-1.htm (EX-99.1) — 14KB
- tm247601d1_ex99-1img01.jpg (GRAPHIC) — 6KB
- 0001104659-24-031470.txt ( ) — 222KB
- fencf-20240229.xsd (EX-101.SCH) — 3KB
- fencf-20240229_lab.xml (EX-101.LAB) — 33KB
- fencf-20240229_pre.xml (EX-101.PRE) — 22KB
- tm248156d1_8ka_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On February 29, 2024, Fennec issued a press release announcing financial results for the fourth quarter and full-year ended December 31, 2023. A copy of the Press Release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference in this Item 2.02. The press release did not include certain financial statements, related footnotes and certain other financial information that will be filed with the Securities and Exchange Commission as part of the Company's Annual Report on Form 10-K. The information and exhibit contained in this Item 2.02 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated February 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 6, 2024 FENNEC PHARMACEUTICALS INC. By: /s/ Rostislav Raykov Rostislav Raykov Chief Executive Officer